Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer.

"Declarations Ethics approval and consent to participateNot applicable. Consent for publicationNot applicable. Competing interestsCMR has consulted regarding oncology drug development with AbbVie, Amgen, AstraZeneca, D2G, Daiichi Sankyo, Epizyme, Genentech/Roche, Ipsen, Jazz Pharmaceuticals, Kowa, Lilly, Merck, and Syros. He serves on the scientific advisory boards of Bridge Medicines, Earli, and Harpoon Therapeutics. MR reports consulting fees from Amgen, AstraZeneca, BeiGene, Boehringer Ingelheim, BMS, Daiichi Sankyo, GSK, Mirati, Merck, MSD, Lilly, Novartis, Pfizer, Sanofi, Roche, and Regeneron; payment or honoraria for lectures, presentations, Speakers Bureaus, manuscript writing, or educational events from Amgen, AstraZeneca, BeiGene, Boehringer Ingelheim, BMS, Daiichi Sankyo, GSK, Mirati, Merck, MSD, Lilly, Novartis, Pfizer, Sanofi, Roche, and Regeneron; support for attending meetings and/or travel from Amgen, AstraZeneca, BeiGene, Boehringer Ingelheim, BMS, Daiichi Sankyo, GSK, Mirati, Merck, MSD, Lilly, Novartis, Pfizer, Sanofi, Roche, and Regeneron; and payments for participation on a Data Safety Monitoring Board or Advisory Board from Sanofi and Daiichi Sankyo. MLJ has received research funding (institutional) from AbbVie, Acerta, Adaptimmune, Amgen, Apexigen, Arcus Biosciences, Array BioPharma, Artios Pharma, AstraZeneca, Atreca, BeiGene, BerGenBio, BioAtla, Black Diamond, Boehringer Ingelheim, Calithera Biosciences, Carisma Therapeutics, Corvus Pharmaceuticals, Curis, CytomX Therapeutics, Daiichi Sankyo, Dracen Pharmaceuticals, Dynavax, Lilly, Elicio Therapeutics, EMD Serono, EQRx, Erasca, Exelixis, Fate Therapeutics, Genentech/Roche, Genmab, Genocea Biosciences, GSK, Gritstone Oncology, Guardant Health, Harpoon Therapeutics, Helsinn Healthcare SA, Hengrui Therapeutics, Hutchison MediPharma, IDEAYA Biosciences, IGM Biosciences, Immunitas Therapeutics, Immunocore, Incyte, Janssen, Kadmon Pharmaceuticals, Kartos Therapeutics, Loxo Oncology, Lycera, Memorial Sloan Kettering, Merck, Merus, Mirati, NeoImmune Tech, Neovia Oncology, Novartis, Numab Therapeutics, Nuvalent, OncoMed Pharmaceuticals, Palleon Pharmaceuticals, Pfizer, PMV Pharmaceuticals, Rain Therapeutics, Regeneron, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Rubius Therapeutics, Sanofi, Seven and Eight Biopharmaceuticals/Birdie Biopharmaceuticals, Shattuck Labs, Silicon Therapeutics, Stemcentrx, Syndax Pharmaceuticals, Takeda, Tarveda, TCR2 Therapeutics, Tempest Therapeutics, Tizona Therapeutics, Tmunity Therapeutics, Turning Point Therapeutics, University of Michigan, Vyriad, and Y-mAbs Therapeutics; and payments to the institution for consulting/advisory roles from AbbVie, Amgen, Arcus Biosciences, ArriVent, Astellas, AstraZeneca, Axelia Oncology, Black Diamond, Calithera Biosciences, Checkpoint Therapeutics, CytomX Therapeutics, Daiichi Sankyo, EcoR1, Editas Medicine, Eisai, Genentech/Roche, Genmab, Genocea Biosciences, GSK, Gritstone Oncology, IDEAYA Biosciences, Immunocore, iTeos, Janssen, Jazz Pharmaceuticals, Lilly, Merck, Mirati, Molecular Axiom, Novartis, Oncorus, Pyramid Biosciences, Regeneron, Revolution Medicines, Ribon Therapeutics, Sanofi-Aventis, Seagen, Takeda, Turning Point Therapeutics, and VBL Therapeutics. FB reports honoraria from Medivation, AstraZeneca, Pfizer, Bayer, Amgen, and Takeda; consulting or advisory role for Medivation, Cell Medica, Amgen, Blueprint Medicines, Pfizer, AbbVie, Janssen, AstraZeneca, and Amgen; participation in Speakers Bureau for Takeda and AstraZeneca; research funding from AstraZeneca (institutional), Boehringer Ingelheim (institutional), Novartis (institutional), Amgen (institutional), Pfizer (institutional), Bristol Myers Squibb (institutional), AbbVie (institutional), Blueprint Medicines, Celgene, PharmaMar (institutional), Merck (institutional), and Mirati (institutional); and travel, accommodation, and expenses from Boehringer Ingelheim. CLH has consulted on oncology drug development with Amgen, AstraZeneca, Daiichi Sankyo, and Puma Biotechnology; served as a consultant for Janssen; and received funding (to institution) from Amgen, AstraZeneca, BMS, and Genentech/Roche. JC-HY reports personal fees and other from Amgen; grants, personal fees, and other from AstraZeneca; personal fees and other from Bayer; personal fees and other from Boehringer Ingelheim; personal fees and other from Bristol Myers Squibb; personal fees and other from Daiichi Sankyo; other from Eli Lilly; personal fees and other from Merck KGaA, Darmstadt, Germany; personal fees and other from Merck Sharp & Dohme; personal fees and other from Novartis; personal fees from Ono Pharmaceuticals; personal fees from Pfizer; personal fees and other from Genentech/Roche; personal fees and other from Takeda Oncology; personal fees and other from Yuhan Pharmaceuticals; other from JNJ, other from Puma Biotechnology; other from Gilead; and other from GSK. LP-A is on the board at Genomica and Altum Sequencing; reports honoraria from Genentech/Roche, Lilly, Pfizer, Bristol Myers Squibb, MSD, AstraZeneca, Merck Serono, PharmaMar, Novartis, Amgen, Sanofi, Bayer, Takeda, Mirati, Daiichi Sankyo, BeiGene, GSK, Janssen, Medscape, and Regeneron; Speakers Bureau participation for MSD Oncology, BMS, Genentech/Roche, Pfizer, Lilly, AstraZeneca, and Merck Serono; research funding from BMS (institutional), AstraZeneca (institutional), PharmaMar (institutional), Kura Oncology (institutional), MSD (institutional), and Pfizer (institutional); and other relationship with Novartis, Ipsen, Pfizer, Servier, Sanofi, Roche, Amgen, and Merck. GB, AG, and JMB are employees of Amgen Inc. JU is a former employee of Amgen Inc. Competing interests CMR has consulted regarding oncology drug development with AbbVie, Amgen, AstraZeneca, D2G, Daiichi Sankyo, Epizyme, Genentech/Roche, Ipsen, Jazz Pharmaceuticals, Kowa, Lilly, Merck, and Syros. He serves on the scientific advisory boards of Bridge Medicines, Earli, and Harpoon Therapeutics. MR reports consulting fees from Amgen, AstraZeneca, BeiGene, Boehringer Ingelheim, BMS, Daiichi Sankyo, GSK, Mirati, Merck, MSD, Lilly, Novartis, Pfizer, Sanofi, Roche, and Regeneron; payment or honoraria for lectures, presentations, Speakers Bureaus, manuscript writing, or educational events from Amgen, AstraZeneca, BeiGene, Boehringer Ingelheim, BMS, Daiichi Sankyo, GSK, Mirati, Merck, MSD, Lilly, Novartis, Pfizer, Sanofi, Roche, and Regeneron; support for attending meetings and/or travel from Amgen, AstraZeneca, BeiGene, Boehringer Ingelheim, BMS, Daiichi Sankyo, GSK, Mirati, Merck, MSD, Lilly, Novartis, Pfizer, Sanofi, Roche, and Regeneron; and payments for participation on a Data Safety Monitoring Board or Advisory Board from Sanofi and Daiichi Sankyo. MLJ has received research funding (institutional) from AbbVie, Acerta, Adaptimmune, Amgen, Apexigen, Arcus Biosciences, Array BioPharma, Artios Pharma, AstraZeneca, Atreca, BeiGene, BerGenBio, BioAtla, Black Diamond, Boehringer Ingelheim, Calithera Biosciences, Carisma Therapeutics, Corvus Pharmaceuticals, Curis, CytomX Therapeutics, Daiichi Sankyo, Dracen Pharmaceuticals, Dynavax, Lilly, Elicio Therapeutics, EMD Serono, EQRx, Erasca, Exelixis, Fate Therapeutics, Genentech/Roche, Genmab, Genocea Biosciences, GSK, Gritstone Oncology, Guardant Health, Harpoon Therapeutics, Helsinn Healthcare SA, Hengrui Therapeutics, Hutchison MediPharma, IDEAYA Biosciences, IGM Biosciences, Immunitas Therapeutics, Immunocore, Incyte, Janssen, Kadmon Pharmaceuticals, Kartos Therapeutics, Loxo Oncology, Lycera, Memorial Sloan Kettering, Merck, Merus, Mirati, NeoImmune Tech, Neovia Oncology, Novartis, Numab Therapeutics, Nuvalent, OncoMed Pharmaceuticals, Palleon Pharmaceuticals, Pfizer, PMV Pharmaceuticals, Rain Therapeutics, Regeneron, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Rubius Therapeutics, Sanofi, Seven and Eight Biopharmaceuticals/Birdie Biopharmaceuticals, Shattuck Labs, Silicon Therapeutics, Stemcentrx, Syndax Pharmaceuticals, Takeda, Tarveda, TCR2 Therapeutics, Tempest Therapeutics, Tizona Therapeutics, Tmunity Therapeutics, Turning Point Therapeutics, University of Michigan, Vyriad, and Y-mAbs Therapeutics; and payments to the institution for consulting/advisory roles from AbbVie, Amgen, Arcus Biosciences, ArriVent, Astellas, AstraZeneca, Axelia Oncology, Black Diamond, Calithera Biosciences, Checkpoint Therapeutics, CytomX Therapeutics, Daiichi Sankyo, EcoR1, Editas Medicine, Eisai, Genentech/Roche, Genmab, Genocea Biosciences, GSK, Gritstone Oncology, IDEAYA Biosciences, Immunocore, iTeos, Janssen, Jazz Pharmaceuticals, Lilly, Merck, Mirati, Molecular Axiom, Novartis, Oncorus, Pyramid Biosciences, Regeneron, Revolution Medicines, Ribon Therapeutics, Sanofi-Aventis, Seagen, Takeda, Turning Point Therapeutics, and VBL Therapeutics. FB reports honoraria from Medivation, AstraZeneca, Pfizer, Bayer, Amgen, and Takeda; consulting or advisory role for Medivation, Cell Medica, Amgen, Blueprint Medicines, Pfizer, AbbVie, Janssen, AstraZeneca, and Amgen; participation in Speakers Bureau for Takeda and AstraZeneca; research funding from AstraZeneca (institutional), Boehringer Ingelheim (institutional), Novartis (institutional), Amgen (institutional), Pfizer (institutional), Bristol Myers Squibb (institutional), AbbVie (institutional), Blueprint Medicines, Celgene, PharmaMar (institutional), Merck (institutional), and Mirati (institutional); and travel, accommodation, and expenses from Boehringer Ingelheim. CLH has consulted on oncology drug development with Amgen, AstraZeneca, Daiichi Sankyo, and Puma Biotechnology; served as a consultant for Janssen; and received funding (to institution) from Amgen, AstraZeneca, BMS, and Genentech/Roche. JC-HY reports personal fees and other from Amgen; grants, personal fees, and other from AstraZeneca; personal fees and other from Bayer; personal fees and other from Boehringer Ingelheim; personal fees and other from Bristo"

"Funding Amgen Inc. CMR is supported by NIH R35CA 263816, U24 CA213274 and P30 CA008748."